

## Sanofi's individual commitments to act4nature international

Through our environmental sustainability program «[Planet Mobilization](#)», we strive to ensure the protection of biodiversity and the equitable and sustainable use of natural resources. While addressing challenges specifically related to our activities, we continue to adapt our practices to always comply with international agreements (e.g. Nagoya Protocol, Convention on Biological Diversity) and to ensure that we do not use endangered natural resources and their derivatives.

### Protect biodiversity and natural resources

- Update [biodiversity](#) risks mapping of our sites: by 2025, our sites located near natural areas defined as sensitive will have a biodiversity protection program<sup>[1]</sup> in partnership with local stakeholders<sup>[2]</sup>. By 2030, all of our sites will foster biodiversity through specific local initiatives.
- Continue to develop our [responsible purchasing](#) policy in terms of environment, with specific consideration of biodiversity:
  - Integrate responsible purchasing criteria<sup>[3]</sup> into the selection and monitoring of our suppliers for 60% of our spending by 2022.
  - As the impact of Greenhouse Gases (GHGs) on biodiversity is global, we are working with our main emitting suppliers [to reduce our Scope 3 emissions](#) by 14% between 2019 and 2030 (see objectives validated by the Science Based Target initiative below).

### Limit our impact on the environment and ecosystems

#### → Product development

- Adopt an [eco-design](#) approach considering all stages of the life cycle from raw materials to end of life for all our new products by 2025, then extend this approach to our top selling products by 2030<sup>[4]</sup>.

#### → Manufacturing of medicines

- Implement management plans<sup>[5]</sup> for [pharmaceutical residues in the environment](#) at all manufacturing sites by 2025 in order to prevent risks to aquatic ecosystems.
- Eliminate the use of landfills in the [management of waste](#) generated by all of our sites by 2025.
- Implement [water management](#) plans at all identified priority sites<sup>[6]</sup> by 2025, then extend this program to all of our industrial sites by 2030.
- Continue the [fight against climate change](#) by achieving carbon neutrality across our entire value chain<sup>[7]</sup> by 2030 and net zero Greenhouse Gas (GHG) emissions by 2050. Our GHG emissions reduction targets are scientifically validated by the *Science Based Target initiative* (-55% of Scope 1 and 2 emissions, -14% Scope 3 between 2019 and 2030). We are also committed to adopting 100% renewable electricity by 2030 (member of *RE100*).

#### → Use by patients and disposal of unused medicines

- Continue to assess the [impact on ecosystems](#) of our top 100 selling<sup>[8]</sup> medicines and all of our new medicines on the market by 2025<sup>[9]</sup>.
- Promote the [responsible use of medicines and the proper disposal of unused medicines, medical devices and packaging](#). Following an exploratory study aimed at mapping current practices on a global scale, we will set up pilot projects based on the good practices identified by 2025. A global program will then be rolled out by 2030.

#### Raise awareness and mobilize our collaborators

- Organize every year [World Environment Day](#) at all of our sites around the world.
- To promote awareness, support the [installation of beehives](#) and the development of spaces dedicated to support local bee populations at our sites around the world.
- Mobilize our employees in our [engagement and collective intelligence program](#) launched in 2020. This program allows all our employees to better understand current environmental issues (including the loss of biodiversity), share initiatives and best practices and jointly design new solutions for the environment financed by the Planet Mobilization Fund. We will ensure that projects are funded annually through the Planet Mobilization Fund and that they are implemented.



1 Aiming to reduce the risks of potential impacts identified during biodiversity risks mapping.

2 Selected using a grid of criteria to identify the most relevant actors.

3 Criteria relating to the fight against climate change and waste management.

4 Number of products to be specified, based on turnover and number of units sold.

5 Monitoring and reduction of emissions.

6 Sites presenting high levels of risk on water, whether physical, regulatory or reputational.

7 Scopes 1, 2 and 3.

8 Based on turnover and number of units sold.

9 The evaluations will be updated regularly to take into account the development of knowledge and may lead to additional measures such as the generation of more in-depth studies in order to refine the evaluations or the communication to the public of environmental information on our medicines.